Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States.

Constantinos I Michaelidis, Richard K Zimmerman, Mary Patricia Nowalk, Kenneth J Smith
Author Information
  1. Constantinos I Michaelidis: University of Pittsburgh School of Medicine, M240 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA. michaelidis.constant@medstudent.pitt.edu.

Abstract

BACKGROUND: There are disparities in influenza and pneumococcal vaccination rates among elderly minority groups and little guidance as to which intervention or combination of interventions to eliminate these disparities is likely to be most cost-effective. Here, we evaluate the cost-effectiveness of four hypothetical vaccination programs designed to eliminate disparities in elderly vaccination rates and differing in the number of interventions.
METHODS: We developed a Markov model in which we assumed a healthcare system perspective, 10-year vaccination program and lifetime time horizon. The cohort was the combined African-American and Hispanic 65 year-old birth cohort in the United States in 2009. We evaluated five different vaccination strategies: no vaccination program and four vaccination programs that varied from "low intensity" to "very high intensity" based on the number of interventions deployed in each program, their cumulative cost and their cumulative impact on elderly minority influenza and pneumococcal vaccination rates.
RESULTS: The very high intensity vaccination program ($24,479/quality-adjusted life year; QALY) was preferred at willingness-to-pay-thresholds of $50,000 and $100,000/QALY and prevented 37,178 influenza cases, 342 influenza deaths, 1,158 invasive pneumococcal disease (IPD) cases and 174 IPD deaths over the birth cohort's lifetime. In one-way sensitivity analyses, the very high intensity program only became cost-prohibitive (>$100,000/QALY) at less likely values for the influenza vaccination rates achieved in year 10 of the high intensity (>73.5%) or very high intensity (<76.8%) vaccination programs.
CONCLUSIONS: A practice-based vaccination program designed to eliminate disparities in elderly minority vaccination rates and including four interventions would be cost-effective.

References

  1. MMWR Morb Mortal Wkly Rep. 2012 Feb 3;61(4):66-72 [PMID: 22298302]
  2. Am J Med. 2002 Sep;113(4):300-7 [PMID: 12361816]
  3. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000422 [PMID: 18253977]
  4. JAMA. 1999 Jan 20;281(3):243-8 [PMID: 9918479]
  5. Healthy People 2000 Stat Notes. 1995 Apr;(7):1-15 [PMID: 11762385]
  6. Vaccine. 2009 May 21;27(24):3159-64 [PMID: 19446186]
  7. Pediatrics. 2000 Jul;106(1 Pt 2):177-83 [PMID: 10888689]
  8. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD000259 [PMID: 22696318]
  9. Value Health. 2013 Mar-Apr;16(2):311-7 [PMID: 23538183]
  10. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876 [PMID: 20166072]
  11. Am J Public Health. 2003 Oct;93(10):1699-705 [PMID: 14534225]
  12. Med Care. 1998 Jun;36(6):778-92 [PMID: 9630120]
  13. Vaccine. 2008 Mar 10;26(11):1420-31 [PMID: 18272262]
  14. Vaccine. 2007 Jun 28;25(27):5086-96 [PMID: 17544181]
  15. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004876 [PMID: 16856068]
  16. Pediatr Infect Dis J. 2005 Jan;24(1):17-23 [PMID: 15665705]
  17. Med Care. 2008 Apr;46(4):349-56 [PMID: 18362813]
  18. Vaccine. 2002 Dec 13;21(3-4):303-11 [PMID: 12450706]
  19. Infect Control Hosp Epidemiol. 2008 May;29(5):385-94 [PMID: 18521990]
  20. Am J Prev Med. 2000 Jan;18(1 Suppl):97-140 [PMID: 10806982]
  21. Med Care. 2006 Nov;44(11):1054-8 [PMID: 17063138]
  22. Public Health Rep. 2010 Jan-Feb;125(1):44-51 [PMID: 20402195]
  23. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003941 [PMID: 16034918]
  24. Eur J Clin Microbiol Infect Dis. 2007 Aug;26(8):531-40 [PMID: 17570001]
  25. Ann Intern Med. 1995 Oct 1;123(7):518-27 [PMID: 7661497]
  26. JAMA. 2004 Sep 15;292(11):1333-40 [PMID: 15367555]
  27. Am J Prev Med. 2005 Jun;28(5 Suppl):248-79 [PMID: 15894160]
  28. Vaccine. 2011 Apr 27;29(19):3525-30 [PMID: 21406266]
  29. Vaccine. 2009 Nov 23;27(50):7110-5 [PMID: 19786135]
  30. Ann Intern Med. 2003 Jun 17;138(12):960-8 [PMID: 12809452]
  31. Natl Vital Stat Rep. 2011 Sep 28;59(9):1-60 [PMID: 22070012]
  32. Vaccine. 2010 Nov 10;28(48):7620-5 [PMID: 20887828]
  33. Arch Fam Med. 1994 Jul;3(7):581-8 [PMID: 7921293]
  34. JAMA. 2003 Jan 8;289(2):179-86 [PMID: 12517228]

MeSH Term

Black or African American
Aged
Cohort Studies
Cost-Benefit Analysis
Health Services for the Aged
Healthcare Disparities
Hispanic or Latino
Humans
Immunization Programs
Influenza, Human
Markov Chains
Minority Groups
Pneumococcal Infections
Quality-Adjusted Life Years
United States
Vaccination

Word Cloud

Created with Highcharts 10.0.0vaccinationratesprogramdisparitiesinfluenzaelderlyhighinterventionseliminateprogramsintensitypneumococcalminorityfourlikelycost-effectivedesignednumberlifetimecohortbirthUnitedStatesintensity"cumulativeyear000/QALYcasesdeathsIPDBACKGROUND:amonggroupslittleguidanceinterventioncombinationevaluatecost-effectivenesshypotheticaldifferingMETHODS:developedMarkovmodelassumedhealthcaresystemperspective10-yeartimehorizoncombinedAfrican-AmericanHispanic65 year-old2009evaluatedfivedifferentstrategies:varied"low"verybaseddeployedcostimpactRESULTS:$24479/quality-adjustedlifeQALYpreferredwillingness-to-pay-thresholds$50000$100prevented371783421158invasivedisease174cohort'sone-waysensitivityanalysesbecamecost-prohibitive>$100lessvaluesachieved10>735%<768%CONCLUSIONS:practice-basedincludingCost-effectiveness

Similar Articles

Cited By